

The role and regulation of the p84 adaptor subunit in phosphatidylinositol 3-kinase γ lipid-kinase signalling and the control of PI3K γ -dependent cell migration

Michelle Elizabeth Turvey, B.Sc. (Biotech) (Hons)

Discipline of Microbiology and Immunology
Department of Molecular and Cellular Biology
School of Biological Sciences
The University of Adelaide

A thesis submitted to The University of Adelaide in fulfilment of
the requirements for the degree of Doctor of Philosophy

2015



Declaration

I, Michelle Turvey certify that this work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Michelle Elizabeth Turvey, B. Sc. (Biotech) (Hons)

May 2015

Acknowledgements

A PhD research project and thesis would be a daunting and near impossible task without the guidance and support of many people along the way. I have been fortunate enough to be surrounded by enthusiastic, determined and knowledgeable work colleagues and a loving and supportive network of family and friends who have made my PhD experience such a rewarding time.

Firstly, I would like to extend a huge thank you to Professor Shaun McColl for accepting me into his lab for Summer Vac, Honours, RA and PhD positions over the many years. On a professional level, you have provided me with valuable lessons in manuscript preparation and grant writing, but above all, your willingness to trust and allow me to work independently through the design and experimentation of my PhD and RA projects taught me so much about the up's, down's and challenges of scientific research. I must also thank you for your acceptance and support of my incessant need to travel and see the world, and for the invaluable work opportunities you provided me with in Canada.

Next I must thank Manuela as my co-supervisor and signal transduction guru. I have learnt so much from you during my PhD and you've been instrumental in keeping me, and my word counts, grounded. The insights and feedback you provided regarding the biochemistry of my work challenged me to extend my conceptualisation of protein signalling. Despite moving on from the lab, you were easily able to continue your support and guidance of my project and made every effort to be available when I needed your help, which I appreciate immensely. Thank you must also go to Peter as my second co-supervisor and his team at the Adelaide Proteomics Centre, who provided me with valuable technical support and endless problem solving help for the challenging phospho-proteomics aspects of my project.

I would also like to thank everyone, both past and present, which I have worked with at the chemokine biology lab. The environment has always been stimulating and supportive, and I have enjoyed learning from so many people with such diverse expertise. Adriana, your lab management skills are unchallenged and I have loved having a bench close to yours to chat about walking tracks, travel destinations and food (and science). To Yuka, Iain and Marina, thank you for offering your help and perspectives on my work, each of you has

supported me both intellectually and creatively during my time in the lab. Next, thanks and a big shout out to the rest of the McColl team; Carly, Kevin, Sarah, Ervin, Cameron, Duncan, Kerrie, Jess, Jasmine, Jade and to past players, Oli, Sarah HJ, Wendel, Julie, Mark, Matt, Brock, Meizhi and Valentina who have all contributed to a lively and enjoyable work environment.

Lastly, a tremendous thank you must go to my family and friends for their continual support during my PhD. To the girls, thanks for the walks, girls' dinners, shared bottles of wine, and adventures around Australia and overseas, you're friendship means the world to me. To Andrew, thank you for your constant love and encouragement, I've had so much fun in all that we've shared so far and can't wait to take on the world with you. Finally, to Mum, Dad and Pip, I could not ask for a more supportive and loving family, so thank you for everything over the last few years, I could not have survived this PhD without you.

Table of contents

Declaration.....	i
Acknowledgements	ii
Table of contents	iv
List of tables.....	xii
Abbreviations	xiii
Publications arising from this work	xvi
Abstract.....	xvii
Chapter 1: Introduction	3
1.1 Overview	3
1.2 Lipid signal transduction.....	4
1.3 The phosphatidylinositol 3-kinase family	6
1.4 Class I PI3Ks	11
1.4.1 The structure of Class I PI3K subunits	11
1.4.2 Regulating the lipid-kinase activity of Class I PI3K enzymes.....	14
1.4.3 Determining the tissue-specific functions of Class I PI3K enzymes	18
1.5 The PI3K Class IB enzyme, PI3Kγ	23
1.5.1 PI3K γ subunits: expression, stability and localisation	24
1.5.2 The interaction between p110 γ and an adaptor subunit	28
1.5.3 Activation of PI3K γ lipid-kinase activity at the plasma membrane	30
1.5.4 Mechanisms of PI3K γ signal regulation	33
1.6 Functional roles for PI3Kγ	35
1.6.1 PI3K γ in cardiac function.....	37
1.6.2 PI3K γ in haematopoietic cell development and function	38
1.6.3 PI3K γ in autoimmunity	41
1.6.4 Roles for Class I PI3K enzymes in cancer initiation and progression	46
1.7 Advances in genome-editing technologies.....	51
1.8 The research project	54
Chapter 2: Methods and materials.....	63
2.1 Mice	63

2.1.1	Housing and maintenance	63
2.1.2	CRISPR gRNA construct design and injection	63
2.1.3	TALEN design and injection	63
2.2	Expression construct design and DNA cloning	64
2.2.1	Cloning p84 expression constructs	64
2.2.2	Site-directed mutagenesis of p84 expression constructs.....	64
2.2.3	Transfection and retroviral transduction of p84 expression vectors.....	65
2.2.4	DNA sequencing.....	65
2.3	Cell lines and <i>ex vivo</i> cell culture	66
2.3.1	MDA.MB.231 and HEK293FT cell culture	66
2.3.2	BMMC culture from total bone marrow isolates.....	66
2.4	<i>In silico</i> analyses.....	67
2.4.1	<i>In silico</i> phospho-prediction database analyses	67
2.4.2	Database mining	67
2.5	<i>In vitro</i> techniques.....	68
2.5.1	Immunoprecipitation and LDS-PAGE.....	68
2.5.2	Coomassie Brilliant Blue staining	69
2.5.3	Western blot analysis	69
2.5.4	Enzyme-linked immunosorbent assay (ELISA)	69
2.5.5	XTT/PMS proliferation assay	70
2.5.6	Soft agar 3D attachment-independent growth assay.....	70
2.5.7	Membrane fractionation.....	70
2.5.8	Incucyte migration assay	71
2.5.9	PCR.....	71
2.5.10	Flow cytometry	72
2.5.11	BMMC β -hexaminidase release assay.....	73
2.5.12	BMMC cytokine release assay	74
2.5.13	<i>In vitro</i> transwell chemotaxis assay	74
2.5.14	<i>In vitro</i> Akt phosphorylation in bone marrow cells.....	74
2.6	<i>In vivo</i> techniques.....	75
2.6.1	Phospho-specific antibody production	75
2.6.2	Experimental haematogenous metastasis.....	75

2.6.3	Induction of chronic MOG ₃₅₋₅₅ -induced EAE.....	76
2.6.4	Induction of relapsing-remitting PLP ₁₃₉₋₁₅₁ -induced EAE.....	76
2.7	Proteomics.....	77
2.7.1	Orbitrap LTQ XL ETD LC-MS for p84 phosphorylation studies	77
2.7.2	<i>In vitro</i> Akt kinase assay	79
2.7.3	Parallel reaction monitoring (PRM).....	79
2.7.4	Isotope-Coded Protein Labelling (ICPL) analyses: Sample preparation	80
2.7.5	ICPL analyses: Labelling, LDS-PAGE and peptide isolation	81
2.7.6	ICPL triplex: HPLC, fraction collection and mass spectrometry	81
2.7.7	ICPL quadruplex: HPLC, fraction collection and mass spectrometry.....	82
2.7.8	ICPL analyses: Determination of peptide and protein ratios	84
2.8	Antibodies and General Reagents	85
2.8.1	Primers and antibodies	85
2.8.2	Phosphate buffered saline (PBS) / Tris buffered saline (TBS)	85
2.8.3	Diethyl Pyrocarbonate (DEPC) reagents for RNA isolation	85
2.8.4	Murine Red Cell Removal Buffer (MRCRB).....	85
2.8.5	PBS/BSA/Azide	86
2.8.6	PBS/Azide	86
2.8.7	Paraformaldehyde solutions (PFA).....	86
2.8.8	NP-40 lysis buffer	86
2.8.9	Tyrodes buffer.....	86
2.8.10	Coomassie Brilliant Blue G-250 (CBB)	86
2.9	Statistical analyses.....	87
Chapter 3: Identification and characterisation of regulatory phosphorylation sites within p84 in the context of PI3Kγ signalling and implications for cell migration..... 95		
3.1	Introduction.....	95
3.2	Results	95
3.2.1	<i>In silico</i> prediction of phosphorylation sites within p84.....	95
3.2.2	Identifying phosphorylation sites within p84.....	96
3.2.3	Development of an expression system to detect and immunoprecipitate wildtype and mutant p84 proteins.....	100

3.2.4	Investigating the tumour suppressor function of p84 and the role of Ser358 and Thr607 phosphorylation sites.....	101
3.2.5	The effect of wildtype and mutant p84 protein expression on PI3K γ signal activation	102
3.2.6	The effect of wildtype and mutant p84 protein expression on MDA.MB.231 cell proliferation and 3D growth.....	103
3.2.7	Assessing the formation of p84/p110 γ heterodimers and their translocation to the membrane	104
3.2.8	Implications of p84 expression on MDA.MB.231 cell migration	106
3.3	Summary.....	107
Chapter 4: Generation, screening and characterisation of a novel p84-deficient mouse (C57Bl/6 <i>Pik3r6</i>^{-/-})		141
4.1	Introduction.....	141
4.2	Results	142
4.2.1	Targeting <i>Pik3r6</i> using CRISPR gene-editing technology.....	142
4.2.2	Screening CRISPR-induced mutations within <i>Pik3r6</i> exon 1	143
4.2.3	Targeting <i>Pik3r6</i> with TALEN gene-editing technology and screening of TALEN-induced mutations	145
4.2.4	Characterising large CRISPR-induced deletions flanking the target site..	146
4.2.5	PI3K γ subunit expression in <i>Pik3r6</i> ^{-/-} tissues	147
4.2.6	Lymphoid organ development in <i>Pik3r6</i> ^{-/-} mice.....	149
4.2.7	Reduced PI3K γ signal activation in <i>Pik3r6</i> ^{-/-} bone marrow-derived cells.	150
4.2.8	The effect of p84 deletion on bone marrow-derived mast cell maturation and function	151
4.2.9	Thymocyte development is unaltered in <i>Pik3r6</i> ^{-/-} mice.....	155
4.2.10	Neutrophil migration is inhibited by the loss of p84 in <i>Pik3r6</i> ^{-/-} mice	155
4.2.11	<i>Pik3r6</i> ^{-/-} mice are protected from EAE disease.....	156
4.3	Summary.....	159
Chapter 5: Quantitative proteome profiling of CNS-infiltrating CD4⁺ Th cells reveals selective changes during experimental autoimmune encephalomyelitis		207

5.1 Introduction.....	207
5.2 Results	210
5.2.1 Isolating CD4 ⁺ cells during EAE disease progression for ICPL labelling	210
5.2.2 ICPL labelling and triplex/quadruplex analyses	211
5.2.3 Validating protein candidates identified to be up-regulated during EAE..	214
5.3 Summary.....	216
Chapter 6: Discussion	235
6.1 The induction of Thr607-dependent p84/p110γ heterodimers represents a regulatory mechanism of PI3Kγ signalling that is required for the tumour suppressor function of p84	238
6.2 Generation of a Pik3r6^{-/-} mouse and characterisation of p84-dependent processes in haematopoietic cell function	251
6.3 Proteomic analyses of CNS-infiltrating CD4⁺ cells during EAE disease	261
6.4 Summary and outlook	263
Appendix A1:.....	271
Appendix A2:.....	273
Appendix A3:.....	275
Appendix A4:.....	277
References:.....	281

List of figures

Figure 1.1: The lipid signalling network.	4
Figure 1.2: Signalling substrates and effectors of Class I, II and III PI3K lipid kinases.....	9
Figure 1.3: Domain structures of Class I, II and III PI3K enzymes.	10
Figure 1.4: Variants of the p85 Class IA PI3K adaptor subunit.	13
Figure 1.5: Proposed structure of Class IB PI3K γ adaptor subunits.....	14
Figure 1.6: Dynamic regulation of PIP ₃ levels	16
Figure 1.7: Crystal structure of the p110 γ catalytic subunit complexed with AS605240. ...	19
Figure 1.8: The p101 and p84 gene locus.....	24
Figure 1.9: The conformation of p110 γ modulates its lipid-kinase activity.....	34
Figure 1.10: CRISPR-Cas targeted gene-editing.....	52
Figure 1.11: TALEN gene-targeting.....	54
Figure 3.1: Assessing p84-specific antibodies.....	111
Figure 3.2: Generating a p84 expression construct with an HA fusion tag.....	113
Figure 3.3: Transient expression of p84-HA in transfected MDA.MB.231 cells.....	115
Figure 3.4: Proteomic analysis of p84-HA precipitated from stimulated MDA.MB.231 cell lysates.	116
Figure 3.5: p84 is constitutively phosphorylated at Serine 358 (Ser358).....	121
Figure 3.6: Identifying Thr607 phosphorylation within p84 <i>in vitro</i>	122
Figure 3.7: Thr607 is part of an Akt phosphorylation consensus site and can be phosphorylated by Akt kinase <i>in vitro</i>	124
Figure 3.8: Akt interacts with p84.	125
Figure 3.9: Generation of a phospho-specific p84 antibody (anti-p84-pThr607).....	126
Figure 3.10: Site-directed mutagenesis of Ser358 and Thr607 residues.	127
Figure 3.11: Validation of S358A and T607A mutations.....	128
Figure 3.12: Stable transduction of MDA.MB.231 cells with p84 retroviral vectors.	130
Figure 3.13: p84 expression limits the metastatic capability of MDA.MB.231 cells in a model of experimental haematogenous metastasis.....	131
Figure 3.14: Expression of wildtype or mutant p84 proteins does not alter PI3K γ signal activation.....	132
Figure 3.15: Expression of p84 does not alter cell proliferation but affects attachment-independent colony formation of MDA.MB.231 cells <i>in vitro</i>	133

Figure 3.16: p84 forms an inducible heterodimer with p110 γ upon CXCL12 stimulation that is dependent on Thr607.....	134
Figure 3.17: Recruitment of p110 γ to the membrane is transient and is not affected by the expression of wildtype p84.	135
Figure 3.18: MDA.MB.231 cells transduced to express mutant p84-T607A are functionally similar to p84 knockdown cells in a model of PI3K γ -dependent migration.....	136
Figure 4.1: CRISPR target design for murine <i>Pik3r6</i> (p84).	162
Figure 4.2: Strategy workflow of CRISPR component injection into C57Bl/6n zygotes.	164
Figure 4.3: Screening for <i>Pik3r6</i> CRISPR-induced mutations within exon 1.....	165
Figure 4.4: Screening CRISPR-induced mutations within exon 1 from <i>Pik3r6</i> CRISPR pups.....	173
Figure 4.5: TALEN design to target murine <i>Pik3r6</i> (p84).	174
Figure 4.6: Screening TALEN-induced mutations within exon 1 from <i>Pik3r6</i> TALEN pups.....	177
Figure 4.7: CRISPR-based gene-targeting can induce large deletions to regions immediately flanking the CRISPR target site.....	178
Figure 4.8: Sequencing PCR of <i>Pik3r6</i> CRISPR pups #1, #5, #7, #16 and #20 confirms large deletions to regions flanking the CRISPR target site.....	181
Figure 4.9: Genomic CRISPR-induced deletion (Δ -10bp) within <i>Pik3r6</i> does not alter the transcript expression of PI3K γ subunits.....	183
Figure 4.10: Genetic mutation of <i>Pik3r6</i> does not destabilise the protein expression of p101 and p110 γ PI3K γ subunits.....	184
Figure 4.11: The weights of lymphoid organs of <i>Pik3r6</i> ^{-/-} mice are comparable to wildtype C57Bl/6n mice.	187
Figure 4.12: Immune cell subsets within lymphoid compartments and the blood of <i>Pik3r6</i> ^{-/-} mice are consistent with wildtype mice.	188
Figure 4.13: <i>Pik3r6</i> ^{-/-} bone marrow cells display inhibited induction of phosphorylated Akt in response to GPCR stimulation.	191
Figure 4.14: p84-deficient bone marrow-derived mast cells are phenotypically similar to wildtype cells and express maturity markers.	192
Figure 4.15: <i>Pik3r6</i> ^{-/-} BMDCs maintain adenosine-mediated potentiation of degranulation and IL-6 cytokine production.....	194

Figure 4.16: <i>Pik3r6</i> ^{-/-} BMMCs display redundancy between p84 and p101 adaptor subunits.	195
Figure 4.17: Thymocyte development is unaffected in <i>Pik3r6</i> ^{-/-} mice.	196
Figure 4.18: <i>Pik3r6</i> ^{-/-} bone marrow-derived neutrophils display reduced migration <i>in vitro</i>	197
Figure 4.19: <i>Pik3r6</i> ^{-/-} mice display attenuated disease upon induction of MOG ₃₅₋₅₅ -induced chronic experimental autoimmune encephalomyelitis.	199
Figure 4.20: Dampened EAE disease severity in <i>Pik3r6</i> ^{-/-} mice is coupled with reduced infiltration of Th cells into the CNS.	201
Figure 4.21: Generation of Th1 and Th17 effector cells is unaffected in <i>Pik3r6</i> ^{-/-} mice during early stage EAE disease compared with wildtype controls.....	202
Figure 5.1: CD4 ⁺ cell sample preparation and ICPL proteomic workflow.	218
Figure 5.2: CD4 ⁺ cell isolation from the CNS during EAE disease progression.	220
Figure 5.3: Examining two EAE disease models: ICPL analysis of CD4 ⁺ cells isolated from the CNS during relapsing-remitting and chronic EAE disease progression.	222
Figure 5.4: Analyses of CNS-infiltrating CD4 ⁺ cells isolated during relapsing-remitting and chronic EAE disease progression identified a broad coverage of regulated proteins.	224
Figure 5.5: Candidate validation by quantitative PCR of mRNA transcript levels.....	231
Figure 6.1: Proposed mechanism of PI3Kγ signalling in MDA.MB.231 cells in response to CXCL12 stimulation.....	250

List of tables

Table 1.1: Common Experimental Inhibitors of Class I PI3Ks	20
Table 1.2: Class I PI3K subunit-deficient genetically-modified mouse strains.	21
Table 1.3: Expression of p84 and p101 subunits in human tissues measured by RT-PCR.	25
Table 2.1: Primers used in this study	88
Table 2.2: Antibodies used in this study	89
Table 2.3: Clinical disease scoring of murine experimental autoimmune encephalomyelitis	91
Table 3.1: Predicted phosphorylation sites within p84.	109
Table 3.2: Summary of post-translational modifications identified within p84.....	118
Table 5.1: Proteins up-regulated by CNS-infiltrating CD4 ⁺ cells during both relapsing- remitting and chronic EAE progression.....	226
Table 5.2: Proteins down-regulated by CNS-infiltrating CD4 ⁺ cells during both relapsing- remitting and chronic EAE progression.....	228
Table 5.3: Established cellular functions of identified regulated proteins.	230

Abbreviations

A2AR	A2A adenosine receptor
A3AR	A3 adenosine receptor
Ab	Antibody
ABD	Adaptor-binding domain
ACN	Acetonitrile
AnxA1/A2	Annexin A1/A2
Arg	Arginine
ATP	Adenosine triphosphate
β -AR	Beta adrenergic receptor
BAD	BCL-2 antagonist of cell death
BCR	B cell receptor
BH	Breakpoint-cluster-region homology
BMMC	Bone marrow-derived mast cell
bp	Base pair
BSA	Bovine serum albumin
C2	Protein-kinase C homology-2 domain
cAMP	Cyclic adenosine monophosphate
CBB	Coomassie Brilliant Blue stain
CCL	CC chemokine ligand
CCR	CC chemokine receptor
CD	Cluster of differentiation
CFA	Complete Freund's adjuvant
CIA	Collagen-induced arthritis
CNA	Copy number alteration
CNS	Central nervous system
ConA	Concanavalin A
CRISPR	Clustered regularly interspaced short palindromic repeat
CXCL	CXC chemokine ligand
CXCR	CXC chemokine receptor
DAG	Diacyl-glycerol
DAVID	Database for Annotation, Visualisation and Integrated Discovery
DEPC	Diethylpyrocarbonate
DN	Double negative (thymocytes)
DP	Double positive (thymocytes)
DTT	Dithiothreitol
EAE	Experimental autoimmune encephalomyelitis
EDTA	Ethylenediaminetetraacetic acid
ELISA	Enzyme-linked immunosorbent assay
ERK1/2	Extracellular signal-related kinases 1/2
ES cell	Embryonic stem cell
EUCOMM	European Conditional Mouse Mutagenesis Program
FA	Formic acid
Fc ϵ RI	Fc epsilon receptor 1
fMLP	Formyl-methionyl-leucyl-phenylalanine
FOXO	Forkhead box O
FRET	Fluorescent resonance energy transfer
GFP	Green fluorescent protein
GPCR	G protein-coupled receptor

gRNA	Guide RNA
GSK-3	Glycogen synthase kinase 3
GTP	Guanosine triphosphate
HA	Haemagglutinin
HBSS	Hank's Balanced Salt Solution
HDX-MS	Hydrogen-deuterium exchange mass spectrometry
HPLC	High-performance liquid chromatography
HRP	Horseradish peroxidase
ICPL	Isotope-coded protein labelling
IFN	Interferon
Ig	Immunoglobulin
IGF-1	Insulin-like growth factor-1
IL	Interleukin
IMVS	Institute of Medical and Veterinary Science
INPP5	Inositol polyphosphate-5-phosphatase
InsP3	Inositol triphosphate
IP	Immunoprecipitation
iSH2	Inter-SH2
KD	Knockdown
kDa	Kilodalton
LCMV	Lymphocytic choriomeningitis virus
LDS-PAGE	Lithium dodecyl sulphate polyacrylamide gel electrophoresis
LPA	Lysophosphatidic acid
Lys	Lysine
mAb	Monoclonal antibody
MALDI-TOF/TOF	Matrix-assisted laser desorption/ionisation time-of-flight MS
MSCV	Murine stem cell virus
MS/MS	Tandem mass spectrometry
Met	Methionine
MOG	Myelin oligodendrocyte glycoprotein
miRNA	Micro RNA
MRCRB	Mouse red cell removal buffer
mRNA	Messenger RNA
MS	Multiple Sclerosis
mTOR	Mammalian target of rapamycin
mTORC1	Mammalian target of rapamycin complex 1
NIP-OVA	Nitroiodophenylacetic acid conjugated to ovalbumin
NLS	Nuclear localisation sequence
NMR	Nuclear magnetic resonance
p-Akt	Phosphorylated Akt
PBS	Phosphate-buffered saline
PCR	Polymerase chain reaction
PDE3B	Phosphodiesterase 3B
PDK-1	Phosphoinositide-dependent kinase 1
PFA	Paraformaldehyde
PH	Pleckstrin homology
PI3K	Phosphatidylinositol 3-kinase
PIP	PtdIns(4)P; PtdIns-4-phosphate
PIP ₂	PtdIns(4,5)P ₂ ; PtdIns-4,5-bisphosphate
PIP ₃	PtdIns(3,4,5)P ₃ ; PtdIns-3,4,5-triphosphate

PKA	Protein kinase A
PKC	Protein kinase C
PKD	Protein kinase D
PLC	Phospholipase C
PLP	Myelin proteolipid protein
PMS	N-methyl dibenzopyrazine methyl sulphate
PMSG	Pregnant mare's serum gonadotropin
PP2A	Protein phosphatase 2
PPMT-1	PP2A methyltransferase-1
PRM	Parallel Reaction Monitoring
PtdIns	Phosphatidyl inositol
PTEN	Phosphatase and tensin homologue
PVDF	Polyvinylidene fluoride (membrane)
PX	Phox homology
qPCR	quantitative PCR
RA	Rheumatoid arthritis
RBD	Ras-binding domain
ROS	Reactive oxygen species
RTK	Receptor tyrosine kinase
RVD	Repeat-variable diresidue
SAGE	South Australian Genome-Editing facility
SCID	Severe Combined Immunodeficient
SDS-PAGE	Sodium dodecyl sulphate polyacrylamide gel electrophoresis
Ser	Serine
SH2	Src homology 2 domain
SH3	Src homology 3 domain
Shh	Sonic hedgehog
SHIP	Src homology 2 domain-containing inositol phosphatase
siRNA	Small interfering RNA
SLE	Systemic lupus erythematosus
SP	Single positive (thymocytes)
S/T	Serine/Threonine
STRING	Search Tool for the Retrieval of Interacting Genes
TALEN	Transactivator-like effector nuclease
T-ALL	T-cell acute lymphoblastic leukemia
TCR	T cell receptor
TBS	Tris-buffered saline
TFA	Trifluoroacetic acid
Th	T helper lymphocyte
Thr	Threonine
TNF	Tumour necrosis factor
Tyr	Tyrosine
VEGF-A	Vascular endothelial growth factor-A
VEGFR1	Vascular endothelial growth factor receptor 1
WB	Western blot
WEHI	Walter and Eliza Hall Institute
WT	Wildtype
XTT	2,3-Bis(2-methoxy-4-nitro-5-sulphophenyl)-2H-tetrazolium-5-carboxanilide

Publications arising from this work

Manuscripts

Turvey ME, Klingler-Hoffmann M, Hoffmann P, McColl SR. p84 forms a negative regulatory complex with p110 γ to control PI3K γ signalling during cell migration. *Immunol Cell Biol.* 2015 Mar. doi; 10.1038/icb.2015.35. (Epub ahead of print).

Refer to **Appendix A1**.

Turvey ME, Koudelka T, Comerford I, Greer JM, Carroll W, Bernard CC, Hoffmann P, McColl SR. Quantitative proteome profiling of CNS-infiltrating autoreactive CD4⁺ cells reveals selective changes during experimental autoimmune encephalomyelitis. *J Proteome Res.* 2014 Aug 1;13(8):3655-70.

Refer to **Appendix A2**.

Conference proceedings

Australian Society for Immunology Annual Scientific Meeting (2013): Poster entitled 'Quantitative proteome profiling of CNS-infiltrating autoreactive CD4⁺ cells reveals selective changes during experimental autoimmune encephalomyelitis'

Australian Society for Immunology (SA / NT Branch) 9th Adelaide Immunology Retreat (2013): Oral Presentation entitled 'The role and regulation of the adaptor subunit p84 in phosphatidylinositol 3-kinase γ signalling and implications for cancer metastasis'

Abstract

The Class IB phosphatidylinositol 3-kinase (PI3K) enzyme, PI3K γ , is activated and recruited to the plasma membrane in response to G protein-coupled receptor stimulation. Upon activation, the lipid-kinase activity and downstream signalling cascades initiated by PI3K γ lead to cytoskeletal rearrangements and the formation of a leading edge for the induction of directed cell migration. PI3K γ consists of the catalytic subunit p110 γ , which forms a mutually exclusive heterodimer with one of two regulatory adaptor subunits, p84 or p101. Although expressed by most cells in the organism, PI3K γ subunits are expressed at highest levels in motile haematopoietic cells, where the regulation of PI3K γ signalling is critical to controlling and maintaining coordinated cell migration during immune responses. Consistent with a central role in leukocyte chemotaxis, innate and adaptive immune cell subsets from p110 γ -deficient mice have been shown to exhibit migration defects *in vitro* and *in vivo*. Furthermore, the aberrant expression of PI3K γ subunits and dysregulation of PI3K γ signalling pathways has been shown to contribute to pathologies such as cancer and autoimmunity where enhanced cell migration promotes disease progression. Despite this, the mechanistic basis for PI3K γ signal regulation is not well understood, particularly with respect to the distinct contributions of the individual regulatory adaptor subunits, p84 and p101. Many PI3K γ -dependent cell functions have been elucidated experimentally using p110 γ - and p101-deficient genetically-modified mouse strains and the PI3K γ -selective inhibitor, AS605240. However, detailed functional data regarding p84 is lacking due to the absence of a p84-deficient mouse strain and limited availability of high quality p84-specific reagents. Three major research goals were addressed in the present study to improve our understanding of the role of p84 in PI3K γ lipid-kinase signalling and its implication in PI3K γ -dependent cell migration.

The first goal was to examine the phosphorylation status of p84 during PI3K γ signalling and assess the role of identified regulatory phosphorylation sites for p84 function using the mammary epithelial carcinoma model cell line, MDA.MB.231. Data presented in this thesis demonstrate that in contrast to the p110 γ and p101 subunits that promote the migration and metastasis of carcinoma cells, the p84 adaptor protein has tumour suppressor function *in vitro* and *in vivo*, which was determined to be dependent on a potential phosphorylation site within p84, Thr607. It was found that Thr607 was required for p84 to form an inducible heterodimer with p110 γ (after initial PI3K γ signal activation) in a

complex sequestered from active signalling at the membrane. This Thr607-dependent p84/p110 γ dimerisation may therefore represent a novel mechanism of negative PI3K γ signal regulation that limits the migration and metastasis of cancer cells.

Next, the contribution of p84 to PI3K γ -dependent immune cell function was determined through the generation and characterisation of a novel p84-deficient mouse (Pik3r6^{-/-}) using CRISPR gene-editing technology. Pik3r6^{-/-} mice were characterised in the context of immune cell development, activation and migration in a variety of haematopoietic cell subsets. It was shown that Pik3r6^{-/-} mice develop normally with respect to lymphoid organ and circulating leukocyte populations at homeostasis. However upon stimulation, neutrophils from Pik3r6^{-/-} mice display reduced migration in response to GPCR agonists *in vitro* and in a murine model of inflammatory autoimmunity (experimental autoimmune encephalomyelitis; EAE), it was found that activated Th lymphocytes display impaired trafficking and reduced infiltration to inflammatory sites.

The final goal was to develop and optimise a proteomic platform to investigate and compare the proteomes of migratory CD4⁺ lymphocytes isolated from tissues at different stages of inflammatory disease progression using experimental autoimmune encephalomyelitis as a model. An isotope-coded protein-labelling (ICPL) approach was developed and optimised to assess the proteomes of CNS-infiltrating CD4⁺ lymphocytes during disease progression in two models of EAE; chronic MOG₃₅₋₅₅-induced EAE and relapsing-remitting PLP₁₃₉₋₁₅₁-induced EAE. This study identified differentially regulated proteins related to immune cell function and represented a initial feasibility study to verify the validity of ICPL as an approach to examine the differential proteomes of wildtype and p84-deficient migratory CD4⁺ lymphocytes during inflammatory disease.

Collectively, the data presented in this thesis represent the identification and characterisation of novel roles for p84 within PI3K γ lipid-kinase signalling during both the regulation of cell migration in carcinoma cells and in haematopoietic cells during immune responses. In addition to furthering the understanding of the unique roles for p84 within PI3K γ signal regulation, the generation of a p84-deficient mouse strain constitutes an important tool to further experimental research in this area.